In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3147-3154

  Hazen, Richard ^a   Harvey, Robert ^a   Ferris, Robert ^a   Craig, Charles ^a   Yates, Phillip ^a   Griffin, Philip ^a   Miller, John ^a   Kaldor, Isrvan ^a   Ray, John ^a   Samano, Vincente ^a   Furfine, Eric ^a,c   Spaltenstein, Andrew ^a   Hale, Michael ^b,d   Tung, Roger ^b,e   St Clair, Marty ^a   Hanlon, Mary ^a   Boone, Lawrence ^a  

^a GLAXOSMITHKLINE   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c Adnexus Therapeutics   (United States)

^d ASTRAZENECA   (United Kingdom)

^e Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BRECANAVIR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SERUM; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS STRAIN;

ALGORITHMS; ANTI-RETROVIRAL AGENTS; BENZODIOXOLES; BLOOD PROTEINS; CARBAMATES; CELL LINE; DRUG RESISTANCE, VIRAL; HELA CELLS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; OROSOMUCOID; PHENOTYPE; SERUM; SERUM ALBUMIN; TYROSINE;

EID: 35948960276     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00401-07     Document Type: Article

References (26)

1. Ammaranond, P., P. Cunningham, R. Oelrichs, K. Suzuki, C. Harris, L. Leas, A. Grulich, D. A. Cooper, and A. D. Kelleher. 2003. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J. Clin. Virol. 26:153-161.
2. Boden, D., and M. Markowitz. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:2775-2783.
3. Daluge, S. M., D. J. M. Purifoy, P. M. Savina, M. H. St. Clair, N. R. Parry, I. K. Dev, P. Novak, K. M. Ayers, J. E. Reardon, G. B. Roberts, J. A. Fyfe, M. R. Blum, D. R. Averett, R. E. Dornsife, B. A. Domin, R. Ferone, D. A. Lewis, and T. A. Krenitsky. 1994. 5-Chloro-2′,3′-dideoxy- 3′-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1590-1603.
4. De Meyer, S., H. Azijn, D. Surleraux, D. Jochmans, A. Tahri, R. Pauweis, P. Wigerinck, and M. de Bethune. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321.
5. Department of Health and Human Services Panel, A Working Group of the Office of AIDS Research Advisory Council. 10 October 2006, posting date. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, http://www.aidsinfo.nih.gov/guidelines.
6. Dumans, A. T., M. A. Soares, D. Pieniazek, M. L. Kalish, V. De Vroey, K. Hertogs, and A. Tanuri. 2002. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob. Agents Chemother. 46:3075-3079.
7. Ferris, R. G., R. J. Hazen, G. B. Roberts, M. H. St. Clair, J. H. Chan, K. R. Romines, G. A. Freeman, J. H. Tidwell, L. T. Schaller, J. R. Cowen, S. A. Short, K. L. Weaver, D. W. Selleseth, K. R. Moniri, and L. Boone. 2005. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 49:4046-4051.
8. Fisher, A. G., E. Collalti, L. Ratner, R. C. Gallo, and F. Wong-Staal. 1985. A molecular clone of HTLV-III with biological activity. Nature 316:262-265.
9. Ford, S. L., Y. S. Reddy, M. T. Anderson, S. C. Murray, P. Fernandez, D. S. Stein, and M. A. Johnson. 2006. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 50:2201-2206.
10. Hanlon, M. H., D. J. T. Porter, E. S. Furfine, A. Spaltenstein, H. L. Carter, D. Danger, A. Y. L. Shu, I. W. Kaldor, J. F. Miller, and V. A. Samano. 2004. Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. Biochemistry 43:14500-14507.
11. Harrigan, P. R., R. S. Hogg, W. W. Y. Dong, B. Yip, B. Wynhoven, J. Woodward, C. J. Bromine, Z. L. Brumme, T. Mo, C. S. Alexander, and J. S. G. Montaner. 2005. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J. Infect. Dis. 191:339-347.
12. Hill, A. V. 1910. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. (London) 40:4-8.
13. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. Schapiro, A. Telenti, and D. Richman. 2005. Update of the drug resistance mutations in HIV-1: 2005. Top. HIV Med. 13:51-57.
14. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66:2232-2239.
15. Little, S. J., E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Hellmann, C. J. Petropoulos, L. Sutton, J. A. Pitt, E. S. Rosenberg, R. A. Koup, B. D. Walker, and D. D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
16. Mager, M. E. 1972. Data analysis in biochemistry and biophysics. Academic Press, New York, NY.
17. Miller, J. F., C. W. Andrews, M. Brieger, E. S. Furfine, M. R. Hale, M. H. Hanlon, R. J. Hazen, I. Kaldor, E. W. McLean, D. Reynolds, D. M. Sammond, A. Spaltenstein, R. Tung, E. M. Turner, R. X. Xu, and R. G. Sherrill. 2006. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg. Med. Chem. Lett. 16:1788-1794.
18. Miller, J. F., E. S. Furfine, M. H. Hanlon, R. J. Hazen, J. A. Ray, L. Robinson, V. Samano, and A. Spaltenstein. 2004. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorg. Med. Chem. Lett. 14:959-963.
19. Miyoshi, I., I. Kubonishi, S. Yoshimoto, T. Akagi, Y. Ohtsuki, Y. Shiraishi, K. Nagata, and Y. Hinuma. 1981. Type C virus particles in a cord T-cell line derived by co-cultivating normal cord leukocytes and human leukaemic T cells. Nature 294:770-771.
20. Molla, A., H. Mo, S. Vasavanonda, L. Han, C. T. Lin, A. Hsu, and D. J. Kempf. 2002. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob. Agents Chemother. 46:2249-2253.
21. Molla, A., S. Vasavanonda, G. Kumar, H. L. Sham, M. Johnson, B. Grabowski, J. F. Denissen, W. Kohlbrenner, J. J. Plattner, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1998. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250:255-262.
22. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, and the HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338: 853-860.
23. Schwartz, O., Y. Henin, V. Marechal, and L. Montagnier. 1988. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res. Hum. Retrovir. 4:441-448.
24. Selleseth, D. W., C. L. Talarico, T. Miller, M. W. Lutz, K. K. Biron, and R. J. Harvey. 2003. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 47:1468-1471.
25. Thaisrivongs, S., and J. W. Strohbach. 1999. Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 51:51-58.
26. Yates, P. J., R. Hazen, M. St. Clair, L. Boone, M. Tisdale, and R. C. Elston. 2006. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. Antimicrob. Agents Chemother. 50:1092-1095.